Physician profile
Lee I Klein
NPI 1932184082
$4,115.38
in general payments reported to CMS, 2019-2025
24 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $226 · 2021: $547 · 2022: $490 · 2023: $362 · 2024: $971 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,183.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $889.31 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $536.00 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $464.57 | 2021-2025 | Tecnis Simplicity, Catalys System, Tecnis Iol |
| Rxsight INC | $342.03 | 2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $286.31 | 2021-2022 | |
| Biotissue Holdings INC. | $277.00 | 2019-2025 | |
| Amgen INC. | $252.64 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $234.66 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $159.29 | 2025 | Vyzulta, Doctors Allergy Formula, Miebo |
| Aerie Pharmaceuticals, INC. | $105.80 | 2019-2021 | |
| Optos, INC. | $98.92 | 2020 | |
| Allergan, INC. | $92.77 | 2020-2022 | |
| Sight Sciences, INC. | $66.69 | 2023-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Optovue, INC. | $65.51 | 2019 | |
| Harrow Eye, LLC | $38.43 | 2025 | Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.73 | 2021-2022 | |
| Ivantis, INC | $23.53 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.39 | 2021 | |
| Dompe US, INC. | $23.09 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $22.12 | 2025 | Xdemvy |
| Shire North American Group INC | $20.29 | 2019 | |
| Eyevance Pharmaceuticals LLC | $20.04 | 2019 | |
| Alcon Research LLC | $18.44 | 2019 | |
| Eyepoint US, INC. | $17.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.